Belite Bio, Inc
BLTE
Rangering i aksjer
#3049
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Aksjekurs
$148.24
Sist synkronisert: 2026-10-19
Markedsverdi
$5.97B
Endring (1 dag)
3.82%
Endring (1 år)
64.04%
Land
US
Handel Belite Bio, Inc (BLTE)
Kategori
Healthcare
Inntekter for Belite Bio, Inc (BLTE)
Inntekter i Jun 2026 TTM: $-102.31M
Ifølge Belite Bio, Inc sine nyeste økonomiske rapporter er selskapets nåværende resultat $-102.31M. I 2023 hadde selskapet et resultat på $-31.62M, en nedgang sammenlignet med resultatet i 2022, som var $-12.65M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Belite Bio, Inc fra 2020 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $-102.31M | 183.11% |
| 2024 | $-36.14M | 14.28% |
| 2023 | $-31.62M | 150.02% |
| 2022 | $-12.65M | 30.85% |
| 2021 | $-9.67M | 68.05% |
| 2020 | $-5.75M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | -5,255.85% |
US
|
|
| $-3.09B | 2,917.33% |
US
|
|
| $-4.02B | 3,825.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,006.63% |
NL
|
